A study [34] reported that EA therapy could reduce depression manifestations in CUMS rats, and the concentration of GFAP protein in their brains as well as the mean optical density of GFAP-immunoreactive astrocytes (GFAP-ir astrocytes) could be increased (n = 20, P < 0.05). The gene discussed is GFAP; the disease is depressive symptom measurement.